Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14163960 | 0.75 | PTGS2 (0.45) | ALDH1A1PTGS2 | |
| SCHEMBL6376816 | 0.75 | PTGS2 (0.45) | ALDH1A1PTGS2 | |
| SCHEMBL2644762 | 0.71 | MAPT (0.42) | MAPTCYP3A4LMNATP53CYP1A2 | |
| SCHEMBL10533506 | 0.70 | MAPT (0.39) | MAPTCYP3A4LMNATP53CYP1A2 | |
| SCHEMBL16046136 | 0.69 | MAPT (0.41) | MAPTCYP3A4LMNATP53CYP1A2 | |
| SCHEMBL6486287 | 0.68 | HTR2B (0.39) | MAPTCYP3A4LMNATP53CYP1A2 | |
| SCHEMBL6672104 | 0.67 | CUL4A (0.40) | MAPTCYP3A4LMNATP53CYP1A2 | |
| SCHEMBL10707636 | 0.64 | MAPT (0.52) | MAPTCYP3A4LMNATP53CYP1A2 | |
| SCHEMBL7159370 | 0.62 | PTPRF (0.36) | MAPTCYP3A4LMNATP53CYP1A2 | |
| Methylphenylsulfone SCHEMBL28046614 | 0.61 | PTGS2 (0.58) | SMN1; SMN2ALDH1A1TDP1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099139-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7432285-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070060571-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7166618-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1246621-A4 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040204471-A1 | Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | US | disclosed |
| WO-2004014431-A1 | A PARENTERAL DOSAGE FORM OF SELECTIVE COX-2 INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-6649629-B2 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NITROMED, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1246621-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | disclosed |
| WO-2001045703-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099139-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NOS2, PTGS2, PTGIS | MAPT 3630/4885CYP3A4 466/4885LMNA 3968/4885 |
| US-20040204471-A1 | Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents | OTC, PTGS2, PTGES2 | MAPT 4485/4885CYP3A4 2364/4885LMNA 2543/4885 |
| US-20070060571-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NOS2, PTGS2, PTGIS | MAPT 3630/4885CYP3A4 466/4885LMNA 3968/4885 |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | PTGS2, PTGS1, PTGES2 | MAPT 4055/4885CYP3A4 52/4885LMNA 2509/4885 |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | PTGS1, PTGS2, PTGES | MAPT 4664/4885CYP3A4 51/4885LMNA 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.